HEALTH OF WOMAN. 2015.6(102):94–96 
 

Homocistein’s level and haemostasis condition as attended markers of fetoplacental exchange 
 

Makarenko M. V., Govseev D. A., Skyrda I. I., Rizhova O. A., Sysa O. N.

Kyiv maternity hospital № 5 
 

In the article are given data of researching the role of hight level gomocisteine in blood, which could result in obstetric complications, and the way of solviny this problems in Maternity Hospital № 5 in Kyiv. There is a connection between increased level of gomocisteine in blood and haemostasis indicators due to tromboelastography. The conducted research allowed to find the reliable criteria of fetoplacental exchange lesion and control the quality of fetoplacental insufficiency treatment. 
 

Key words: gomocisteine, haemostasis, fetoplacental insufficiency, endothelial disfunction. 
 

REFERENCES

1. Шмелева ВМ, Капустин СИ, Блинов МН, Папаян ЛП. 2003. Гипергомоцистеинемия – значимый фактор риска развития артериальных и венозных тромбозов. Медицинский академический журнал 3:28–34.

2. Шмелева ВМ, Смирнова ОА, Гуржий АА, Сливанкова ЕВ, Папаян ЛП. 2007. Влияние комбинированных гормональных контрацептивов на уровень гомоцистеина плазмы. Клинико-лабораторный консилиум 16:26–30.

3. Макацария АД, Бицадзе ВО. 2001. Тромбофилические состояния в акушерской практике. М:703.

4. Carmel R, D.W. Jacobsen. 2001. Homocysteine in Health and Disease. Cambridge University Press:500.

5. Lissade-Lavigne G, Cochery-Nouvellon E, Mercier E et al. 2005. The association between hereditary thrombophilias and pregnancy loss. Haematologica 90(9):1223–1230.

6. Rasmussen K, Moller J, Lyngbak M et al. 1996. Age and gender specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin. Chem. 42:630–636.

7. Shmeleva VM, Kapustin SI, Alabieva EA, Plughnikova TA. 2007. Prevalence of thrombophilia in women with pregnancy loss and gestational outcome in women with diagnosed thrombophilia following antithrombotic therapy. J. Thromb. Haemost. 5(2):W-592.